Add BrightSurf on Google Email

American Society of Nephrology


Muscle mass may not fully explain higher creatinine in blacks with kidney disease

Researchers found that higher creatinine levels in black patients with kidney disease cannot be explained by differences in muscle mass. The study suggests new theories are needed to account for the racial difference, which could help explain why blacks are more affected by progressive chronic kidney disease.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateApr 16, 2008

Chronic kidney disease should not prevent women from taking the osteoporosis drug raloxifene

A study published in the Journal of the American Society Nephrology found that raloxifene increases bone mineral density and reduces vertebral fractures in postmenopausal women with mild to moderate chronic kidney disease. The medication is safe and effective for this patient population, reversing bone loss and fracture risk.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateApr 9, 2008

Race, insurance status affect access to transplantation and kidney disease treatment

Two studies suggest that universal access to healthcare can reduce racial and ethnic barriers to treatment for kidney disease. Minority patients and those on Medicare or with less education had longer dialysis times before being wait-listed, highlighting the need for improved insurance coverage.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateFeb 27, 2008

Kidney donor age linked to aortic siffening

A new study has found that kidney donor age is associated with increased aortic stiffness in recipients, which may explain higher rates of cardiovascular disease and death. The study suggests that targeted interventions after kidney transplantation could improve long-term results by reducing cardiovascular risk and mortality.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateFeb 21, 2008

Pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease

Chronic kidney disease significantly increases the risk of cardiovascular events in diabetic patients. Pioglitazone has been shown to lower this risk, particularly among those with moderate to severe renal disease. The study found that pioglitazone reduced all-cause death, myocardial infarction, and stroke by one-third.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateDec 12, 2007

Study questions impact of hemoglobin variations on mortality in dialysis patients

A recent study published in the Clinical Journal of the American Society of Nephrology suggests that persistently low hemoglobin levels in dialysis patients increase their risk of death, while fluctuating levels do not. The research used data from nearly 160,000 patients to analyze the effects of hemoglobin variability on mortality rates.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateDec 5, 2007

Early intervention dramatically improves outcomes for new dialysis patients

A study found that a structured quality improvement program called RightStart improved outcomes for new dialysis patients, including significant reductions in mortality and hospitalization rates. The program, which included education, close medical follow-up, and self-empowerment, was associated with better nutrition, less anemia, and ...

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateOct 18, 2007

Obesity linked to hyperparathyroidism in chronic kidney disease

A study found that obesity is associated with higher levels of parathyroid hormone in patients with moderate to severe chronic kidney disease. Weight loss may help lower PTH levels, while other treatments could lead to weight loss. The association was strongest in patients with signs of malnutrition and inflammation.

SourceAmerican Society of Nephrology·JournalClinical Journal of the American Society of Nephrology·DateAug 8, 2007

Combination therapy stops loss of kidney function in rare genetic disease

Researchers have discovered that combining two blood pressure-lowering drugs with enzyme replacement therapy can slow the progression of kidney disease in patients with severe Fabry disease. The study found significant reductions in proteinuria and minimal decline in kidney function after an average of two and a half years' treatment.

SourceAmerican Society of Nephrology·JournalJournal of the American Society of Nephrology·DateJul 25, 2007